For the treatment of relapsing-remitting multiple sclerosis, what does first-line therapy typically involve?

First-line therapy for relapsing-remitting multiple sclerosis typically involves the use of immunomodulators. These medications are designed to modify the immune system's activity, thereby reducing the frequency and severity of relapses in this condition. Examples of first-line immunomodulators include interferon beta and glatiramer acetate, which have been shown to effectively decrease the rate of exacerbations and slow disease progression in patients with relapsing-remitting MS.

Other options, such as focusing solely on Natalizumab, do not encompass the broader category of first-line treatments since Natalizumab is generally reserved for more aggressive cases due to its higher efficacy and risk profile. Similarly, while monitoring renal function is important in certain treatments, it is not relevant as a primary treatment modality for relapsing-remitting MS. Lastly, intravenous administration of Fingolimod is not standard as Fingolimod is typically taken orally, making it less appropriate as a first-line therapy in the context of relapsing-remitting MS. Thus, the use of an immunomodulator represents the established and comprehensive approach for initial treatment in this patient population.